Labelling of amphetamines with /sup 123/I

Within the past decade two important groups of radiopharmaceuticals labelled with /sup 123/I were introduced into the clinical application opening new areas of metabolic studies in nuclear medicine: radioiodinated fatty acids were developed for metabolic studies of the myocardium and radioiodinated amphetamine derivatives were prepared for studying brain diseases by means of SPECT. It must be emphasized that the radiochemical problems with both groups of compounds are practically the same since both are radioiodinated by a nucleophilic substitution mechanism using /sup 123/I directly in its anionic form. The clinical application of brain imaging agents, particularly the one of p-/sup 123/I-iodo-N-isopropylamphetamine, is important and will presumably increase as soon as the details of the individual biochemical steps, which are involved in brain uptake mechanisms, are evaluated. It is felt that the potential of the clinical IMP application is greater than the recent use of this radiopharmaceutical